Tags

Type your tag names separated by a space and hit enter

Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus.
Gastroenterology 2008; 134(4):981-7G

Abstract

BACKGROUND & AIMS

Information on the clinical profile of pancreatic cancer (PaC) associated diabetes (DM) is limited. We compared the prevalence and clinical characteristics of DM in subjects with and without PaC.

METHODS

We prospectively recruited 512 newly diagnosed PaC cases and 933 controls of similar age, who completed demographic and clinical questionnaires and had fasting blood glucose (FBG) levels measured at recruitment and after pancreaticoduodenectomy (n = 105). Subjects with a FBG level >126 mg/dL or who were on antidiabetic treatment were classified as having DM.

RESULTS

DM was more prevalent (47% vs 7%; P < .001) and predominantly of new onset (<2-year duration) (74% vs 53%; P = .002) among cases compared with controls. Among PaC cases, those with DM (n = 243) were older (68 +/- 10 vs 64 +/- 12 years; P < .001), reported higher usual adult body mass index (30 +/- 6 vs 27 +/- 5 kg/m(2); P < .001), and had a greater frequency of family history of DM (47% vs 31%; P < .001) compared with those without DM (n = 269). After pancreaticoduodenectomy, while DM resolved in 17 of 30 patients (57%) with new-onset DM, its prevalence was unchanged in patients with long-standing DM (n = 11) (P = .009).

CONCLUSIONS

PaC is a powerful diabetogenic state; DM associated with PaC is often new-onset, resolves following cancer resection, and appears to be associated with conventional risk factors for DM. New-onset DM in patients with PaC is likely induced by the tumor.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18395079

Citation

Pannala, Rahul, et al. "Prevalence and Clinical Profile of Pancreatic Cancer-associated Diabetes Mellitus." Gastroenterology, vol. 134, no. 4, 2008, pp. 981-7.
Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981-7.
Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., & Chari, S. T. (2008). Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology, 134(4), pp. 981-7. doi:10.1053/j.gastro.2008.01.039.
Pannala R, et al. Prevalence and Clinical Profile of Pancreatic Cancer-associated Diabetes Mellitus. Gastroenterology. 2008;134(4):981-7. PubMed PMID: 18395079.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. AU - Pannala,Rahul, AU - Leirness,Jeffery B, AU - Bamlet,William R, AU - Basu,Ananda, AU - Petersen,Gloria M, AU - Chari,Suresh T, Y1 - 2008/01/18/ PY - 2007/08/13/received PY - 2008/01/10/accepted PY - 2008/4/9/pubmed PY - 2008/4/25/medline PY - 2008/4/9/entrez SP - 981 EP - 7 JF - Gastroenterology JO - Gastroenterology VL - 134 IS - 4 N2 - BACKGROUND & AIMS: Information on the clinical profile of pancreatic cancer (PaC) associated diabetes (DM) is limited. We compared the prevalence and clinical characteristics of DM in subjects with and without PaC. METHODS: We prospectively recruited 512 newly diagnosed PaC cases and 933 controls of similar age, who completed demographic and clinical questionnaires and had fasting blood glucose (FBG) levels measured at recruitment and after pancreaticoduodenectomy (n = 105). Subjects with a FBG level >126 mg/dL or who were on antidiabetic treatment were classified as having DM. RESULTS: DM was more prevalent (47% vs 7%; P < .001) and predominantly of new onset (<2-year duration) (74% vs 53%; P = .002) among cases compared with controls. Among PaC cases, those with DM (n = 243) were older (68 +/- 10 vs 64 +/- 12 years; P < .001), reported higher usual adult body mass index (30 +/- 6 vs 27 +/- 5 kg/m(2); P < .001), and had a greater frequency of family history of DM (47% vs 31%; P < .001) compared with those without DM (n = 269). After pancreaticoduodenectomy, while DM resolved in 17 of 30 patients (57%) with new-onset DM, its prevalence was unchanged in patients with long-standing DM (n = 11) (P = .009). CONCLUSIONS: PaC is a powerful diabetogenic state; DM associated with PaC is often new-onset, resolves following cancer resection, and appears to be associated with conventional risk factors for DM. New-onset DM in patients with PaC is likely induced by the tumor. SN - 1528-0012 UR - https://www.unboundmedicine.com/medline/citation/18395079/Prevalence_and_clinical_profile_of_pancreatic_cancer_associated_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(08)00113-3 DB - PRIME DP - Unbound Medicine ER -